AbbVie Inc. (BCBA:ABBV)

Market Cap	377.20T
Revenue (ttm)	61.56T
Net Income (ttm)	4.46T
Shares Out	n/a
EPS (ttm)	2,510.97
PE Ratio	84.60
Forward PE	14.90
Dividend	488.77 (2.22%)
Ex-Dividend Date	Apr 15, 2025

Volume	985
Average Volume	1,229
Open	21,600
Previous Close	21,300
Day's Range	21,550 - 22,300
52-Week Range	12,412 - 27,925
Beta	n/a
RSI	44.51
Earnings Date	Apr 25, 2025

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2012
• Employees: 55,000
• Stock Exchange: Buenos Aires Stock Exchange
• Ticker Symbol: ABBV

Financial Performance

In 2024, AbbVie's revenue was $56.33 billion, an increase of 3.71% compared to the previous year's $54.32 billion. Earnings were $4.24 billion, a decrease of -12.07%.

Financial numbers in USD